Amplia Therapeutics Limited (ASX:ATX, OTCQB:INNMF), (“Amplia” or the “Company”), announces Board changes further to a Board renewal and succession plan. Dr Warwick Tong will retire as Board Chairman ...

Amplia Therapeutics has handed the chairman’s role to Jane Bell AM as pancreatic cancer trial results and US regulatory ...

Insiders who purchased Amplia Therapeutics Limited (ASX:ATX) shares in the past 12 months are unlikely to be deeply impacted by the stock's 10.0% decline over the past week. After taking the recent ...

Amplia Therapeutics ( (AU:ATX)) has provided an update. Amplia Therapeutics has announced a planned change in board leadership as part of its renewal and succession strategy, with long-serving ...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring ...

Amplia Therapeutics Ltd. (AU:ATX) has released an update. Amplia Therapeutics Ltd. has announced the proposed issuance of new securities, including options priced at $0.1725 set to expire on October ...

Melbourne, Australia, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF) ("Amplia” or the "Company”) is pleased to announce that the Company’s CMO Dr Jason Lickliter ...

Amplia Therapeutics Ltd. (AU:ATX) has released an update. Amplia Therapeutics Ltd. has successfully completed the allotment of over 67 million shares at $0.115 each, raising $13 million through an ...

For everyday punters looking at medical technology companies, the best opportunities often come from identifying a drug that makes other multi-billion-dollar treatments work better. That is the main ...

Amplia Therapeutics Ltd (ASX:ATX) achieved multiple clinical and manufacturing milestones during the December quarter, setting the company up for a busy 2022 with Phase 2 clinical trials for AMP945 ...